The Food and Drug Administration on Thursday granted accelerated approval to a new dual-acting drug from Amgen to treat small cell lung cancer in people whose disease has progressed following ...
Small cell lung cancer typically responds to chemotherapy, but relapse of this aggressive type of cancer is common and the second-line treatment options offer limited benefit. FDA approval of a ...
Donanemab could be the second amyloid antibody drug approved to treat early-stage Alzheimer’s disease. The drug slowed ...
A committee of independent advisers to the Food and Drug Administration voted unanimously Monday that the benefits outweigh ...
There isn’t a cure for Alzheimer’s disease, the most common form of dementia in the U.S., but a third treatment for the ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly ...
A U.S. Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug ...
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly, tarlatamab (Imdelltra) is only for patients who ...